c-MET (H1094Y)

MET · Variant type: point · HGVS: p.H1094Y

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Tepotinib	97.8%	2.2%	99.75
2	Capmatinib	96.2%	3.8%	99.75
3	Deucravacitinib	90.0%	10.0%	98.99
4	Erdafitinib	67.4%	32.6%	95.71
5	Tivozanib	65.6%	34.4%	92.42
6	Gilteritinib	63.9%	36.1%	88.97
7	Pacritinib	45.7%	54.3%	88.64
8	Sunitinib	35.5%	64.5%	91.73
9	Defactinib	31.0%	69.0%	92.68
10	Selpercatinib	28.9%	71.1%	96.72
11	Neratinib	25.4%	74.6%	93.18
12	Avapritinib	20.7%	79.3%	97.73
13	Fedratinib	20.4%	79.6%	96.21
14	Repotrectinib	19.2%	80.8%	84.21
15	Canertinib	17.5%	82.5%	96.49
16	Ripretinib	15.7%	84.3%	92.95
17	Pexidartinib	13.9%	86.1%	99.49
18	Asciminib	10.2%	89.8%	100.00
19	Entrectinib	8.1%	91.9%	93.69
20	Pralsetinib	7.8%	92.2%	93.43
21	Abemaciclib	7.4%	92.6%	91.48
22	Zanubrutinib	7.4%	92.6%	98.24
23	Upadacitinib	7.2%	92.8%	97.98
24	Tucatinib	6.3%	93.7%	99.75
25	Abrocitinib	6.3%	93.7%	99.50

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Tepotinib	97.8%	—	—
Capmatinib	96.2%	—	—
Deucravacitinib	90.0%	—	—
Erdafitinib	67.4%	—	—
Tivozanib	65.6%	—	—
Gilteritinib	63.9%	—	—
Pacritinib	45.7%	—	—
Sunitinib	35.5%	—	—
Defactinib	31.0%	—	—
Selpercatinib	28.9%	—	—
Neratinib	25.4%	—	—
Avapritinib	20.7%	—	—
Fedratinib	20.4%	—	—
Repotrectinib	19.2%	—	—
Canertinib	17.5%	—	—
Ripretinib	15.7%	—	—
Pexidartinib	13.9%	—	—
Asciminib	10.2%	—	—
Entrectinib	8.1%	—	—
Pralsetinib	7.8%	—	—
Abemaciclib	7.4%	—	—
Zanubrutinib	7.4%	—	—
Upadacitinib	7.2%	—	—
Tucatinib	6.3%	—	—
Abrocitinib	6.3%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 15.6ms